Your browser doesn't support javascript.
loading
Evaluation of Free Valproate Concentration in Critically Ill Patients.
Brown, Caitlin S; Liu, JiTong; Riker, Richard R; Mara, Kristin C; Rabinstein, Alejandro A; Fraser, Gilles L; May, Teresa L; Seder, David; Gagnon, David J.
Afiliación
  • Brown CS; Department of Pharmacy, Mayo Clinic, Rochester, MN.
  • Liu J; Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA.
  • Riker RR; Department of Critical Care Services, Maine Medical Center, Portland, ME.
  • Mara KC; Tufts University School of Medicine, Boston, MA.
  • Rabinstein AA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
  • Fraser GL; Division of Neurology, Mayo Clinic, Rochester, MN.
  • May TL; (ret.).
  • Seder D; Department of Critical Care Services, Maine Medical Center, Portland, ME.
  • Gagnon DJ; Tufts University School of Medicine, Boston, MA.
Crit Care Explor ; 4(9): e0746, 2022 Sep.
Article en En | MEDLINE | ID: mdl-37942235
ABSTRACT
Protein binding of valproate is variable in ICU patients, and the total valproate concentration does not predict the free valproate concentration, even when correcting for albumin. We sought to quantify valproate free concentration among ICU patients, identify risk factors associated with an increasing free valproate concentration, and evaluate the association between free valproate concentration with potential adverse drug effect.

DESIGN:

Retrospective multicenter cohort study.

SETTING:

Two academic medical centers. PATIENTS Patients greater than or equal to 18 years of age with concomitant free and total valproate concentrations collected in the ICU.

INTERVENTIONS:

None. MEASUREMENTS AND MAIN

RESULTS:

Two-hundred fifty-six patients were included in the study, with a median age of 56 years (42-70) and 65% of patients were male. The median total valproate concentration was 53 µg/mL (38-70 µg/mL), the free valproate concentration was 12 µg/mL (7-20 µg/mL), and the free fraction was 23.6% (17.0-33.9%). Therapeutic discordance between the free and total valproate concentration occurred in 70% of patients. On multivariable analysis, increased free valproate concentration was associated with higher total valproate concentration (per 5 µg/mL increase, increase 1.72 µg/mL, 95% CI, 1.48-1.96) and lower serum albumin (per 1 g/dL decrease, increase 4.60 µg/mL, 95% CI, 2.71-6.49). There was no association between free valproate concentration and adverse effects.

CONCLUSIONS:

The valproate total and free concentration was discordant in the majority of patients (70%). Increased valproate free concentration was associated with hypoalbuminemia and total valproate concentration. Clinical decisions based on total valproate concentration may be incorrect for many ICU patients. Prospective, controlled studies are needed to confirm these findings and their clinical relevance.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crit Care Explor Año: 2022 Tipo del documento: Article País de afiliación: Mongolia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crit Care Explor Año: 2022 Tipo del documento: Article País de afiliación: Mongolia